Second Line Treatment Decision as Per Standard of Care or Foundation Medicine in Patients With Locally Advanced or Metastatic Non‐Small Cell Lung Cancer

Key Points

• This research aims to evaluate the impact of Foundation Medicine (FMI) genomic profiling on treatment decisions for advanced non-small cell lung cancer (NSCLC).
• Utilized FMI genomic profiling data to assess treatment pathways.
• Compared treatment decisions between standard of care (SOC) and FMI recommendations.
• Directed eligible patients towards clinical trials based on their genomic data.
• Clinicians modified management strategies for several NSCLC patients.
• FMI identified actionable mutations that SOC approaches missed.
• The findings highlight FMI's potential to enhance personalized medicine in NSCLC treatment.

Abstract